Skip to main content

Table 4 Injection site reactions in 20 patients who received at least one vaccination

From: HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

Injection sites

Number (%)

Swelling

<4

0 (0%)

4-8

13 (65%)

>8

7 (35%)

Erythema

mild

4 (20%)

moderate

16 (80%)

severe

0 (0%)

Temp

mild

4 (20%)

moderate

15 (75%)

severe

1 (5%)

Pain

mild

17 (85%)

moderate

3 (15%)

severe

0 (0%)

Itching

mild

17 (85%)

moderate

3 (15%)

severe

0 (0%)

Ulceration

0 (0%)

  1. All the injection sites were scored 1 hour after administration of the vaccine. The pain and itching is scored at the following visit (i.e. 3 weeks after the vaccination by using the diary). Only the maximal injection site reaction per patient is scored.